Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 44

2.

Selegiline for Alzheimer's disease.

Birks J, Flicker L.

Cochrane Database Syst Rev. 2003;(1):CD000442. Review.

PMID:
12535396
3.

Selegiline for Alzheimer's disease.

Birks J, Flicker L.

Cochrane Database Syst Rev. 2000;(2):CD000442. Review. Update in: Cochrane Database Syst Rev. 2003;(1):CD000442.

PMID:
10796544
4.

L-deprenyl in the treatment of mild dementia of the Alzheimer type: results of a 15-month trial.

Burke WJ, Roccaforte WH, Wengel SP, Bayer BL, Ranno AE, Willcockson NK.

J Am Geriatr Soc. 1993 Nov;41(11):1219-25. Review.

PMID:
8227897
5.
6.

Selegiline in treatment of behavioral and cognitive symptoms of Alzheimer disease.

Tolbert SR, Fuller MA.

Ann Pharmacother. 1996 Oct;30(10):1122-9. Review.

PMID:
8998375
7.

Propentofylline in the treatment of vascular dementia and Alzheimer-type dementia: overview of phase I and phase II clinical trials.

Mielke R, Möller HJ, Erkinjuntti T, Rosenkranz B, Rother M, Kittner B.

Alzheimer Dis Assoc Disord. 1998;12 Suppl 2:S29-35. Review.

PMID:
9769027
8.
9.

Clinical trials in dementia with propentofylline.

Kittner B, Rössner M, Rother M.

Ann N Y Acad Sci. 1997 Sep 26;826:307-16. Review.

PMID:
9329701
10.

The clinical potential of Deprenyl in neurologic and psychiatric disorders.

Kuhn W, Müller T.

J Neural Transm Suppl. 1996;48:85-93. Review.

PMID:
8988464
11.

Propentofylline in the treatment of Alzheimer's disease and vascular dementia: a review of phase III trials.

Rother M, Erkinjuntti T, Roessner M, Kittner B, Marcusson J, Karlsson I.

Dement Geriatr Cogn Disord. 1998 Jul;9 Suppl 1:36-43. Review.

PMID:
9716243
12.

Thiamine for Alzheimer's disease.

Rodríguez-Martín JL, López-Arrieta JM, Qizilbash N.

Cochrane Database Syst Rev. 2000;(2):CD001498. Review. Update in: Cochrane Database Syst Rev. 2001;(2):CD001498.

PMID:
10796655
13.

Age-related memory decline and longevity under treatment with selegiline.

Stoll S, Hafner U, Pohl O, Müller WE.

Life Sci. 1994;55(25-26):2155-63. Review.

PMID:
7997074
14.

Possible mechanisms of action of (-)deprenyl and other MAO-B inhibitors in some neurologic and psychiatric disorders.

Berry MD, Juorio AV, Paterson IA.

Prog Neurobiol. 1994 Oct;44(2):141-61. Review. No abstract available.

PMID:
7831475
15.

[A critical review of available tools for evaluating memory enhancers in Alzheimer's disease].

Poitrenaud J, Kalafat M, Israel L, Guez D.

Rev Med Interne. 1997;18(1):59-71. Review. French.

PMID:
9092020
16.

Canine cognitive dysfunction as a model for human age-related cognitive decline, dementia and Alzheimer's disease: clinical presentation, cognitive testing, pathology and response to 1-deprenyl therapy.

Ruehl WW, Bruyette DS, DePaoli A, Cotman CW, Head E, Milgram NW, Cummings BJ.

Prog Brain Res. 1995;106:217-25. Review. No abstract available.

PMID:
8584657
17.

Chronic oral physostigmine without lecithin improves memory in Alzheimer's disease.

Thal LJ, Masur DM, Blau AD, Fuld PA, Klauber MR.

J Am Geriatr Soc. 1989 Jan;37(1):42-8. Review.

PMID:
2642499
18.

Lecithin and memory training in suspected Alzheimer's disease.

Brinkman SD, Smith RC, Meyer JS, Vroulis G, Shaw T, Gordon JR, Allen RH.

J Gerontol. 1982 Jan;37(1):4-9. Review.

PMID:
7031118
19.

Neuroprotection by selegiline and other MAO inhibitors.

Stern G.

J Neural Transm Suppl. 1998;52:99-107. Review.

PMID:
9564613
20.

Clinical global impressions in Alzheimer's clinical trials.

Schneider LS, Olin JT.

Int Psychogeriatr. 1996 Summer;8(2):277-88; discussion 288-90. Review.

PMID:
8994897
Items per page

Supplemental Content

Write to the Help Desk